We recently published a list of Was Jim Cramer Right About These 9 Stocks? In this article, we are going to take a look at ...

This one-time weight-loss drug leader has suffered several setbacks lately. It isn't wise to count out this veteran ...

In the past, studies in type-2 diabetes patients have linked Ozempic to the condition called non-arteritic anterior ischemic ...

The Indianapolis-based drugmaker sees orforglipron as a potential global breakthrough treatment for weight loss and other ...

Human insulin presents Indian companies an opportunity estimated at Rs 450 crore per annum in India and $157 million/annum in ...

Shares in pharmaceuticals group Novo Nordisk (NVO) remained in good shape today despite reports that its weight loss drugs ...

Eli Lilly and Camurus have entered into partnership worth up to $870m to develop long-acting therapies in cardiometabolic ...

A recent report suggested that more American teenagers now use the weight-loss drug Wegovy.However, experts stated that its ...

House appropriators advanced a bill to fund the FDA for fiscal 2026 on a party-line vote out of a subcommittee Thursday — but ...

The novel selective antibody sibeprenlimab reduced proteinuria more than any prior drug for IgA nephropathy, with excellent ...

Breakingviews provides financial professionals with unique agenda-setting insight on the major financial news stories as they ...

Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from $650 to $499 for uninsured patients or people ...